Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet
Reuters

Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet

Nov 16 (Reuters) - Eli Lilly has agreed to acquire privately held biotech Calytrix Bio for up to $1.5 billion in cash, as it looks to expand the development of treatments for rare blood cancers. The move, announced on Monday by Calytrix, is the latest in a string of acquisitions by the Indianapolis-
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.